Literature DB >> 16472423

[Non recurrent laryngeal nerve. Personal experience].

C Sciumè1, G Geraci, F Pisello, F Li Volsi, T Facella, A Licata, G Modica.   

Abstract

PURPOSE: Damage to the recurrent laryngeal nerve (RLN) during thyroid or parathyroid surgery is the most common iatrogenic cause of vocal cord paralysis. Identification of the RLNs and meticulous surgical technique can significantly decrease the incidence of this complication. Nonrecurrent RLNs (NRRLNs) are exceedingly rare. Surgeons need to be aware of their position to avoid injuries. PATIENT AND METHODS: A retrospective review of 263 right RLN exposures (and 251 left RNL) over a 5-year period was performed.
RESULTS: Two NRRLNs were encountered, for an incidence of 0.39% (0.76% only for right dissection), without anatomic anomalies on the left side. The nerve anomaly was never preoperatively diagnosed.
CONCLUSION: NRRLNs are rare and is associated with a right subclavian artery arising from distal aortic arch. Awareness of their existence and correct surgical technique will prevent the surgeon from accidentally lesion of NRRLN one if it is encountered during thyroid or parathyroid surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16472423

Source DB:  PubMed          Journal:  G Chir        ISSN: 0391-9005


  3 in total

1.  Non-recurrent laryngeal nerve.

Authors:  Fahri Yetişir; Alper Bilal Özkardeş; Halit Ziya Dündar; Bozkurt Birkan; Ahmet Burak Çiftci; Mehmet Kılıç
Journal:  Ulus Cerrahi Derg       Date:  2013-05-28

2.  Preoperative computed tomography diagnosis of non-recurrent laryngeal nerve in patients with esophageal carcinoma.

Authors:  Zhong-Xi Niu; Hang Zhang; Long-Qi Chen; Hui Shi; Jun Peng; Li-Wei Su; Wei Li; Bo Xiao; Shu He; Hong-Xu Yue
Journal:  Thorac Cancer       Date:  2016-12-02       Impact factor: 3.500

3.  The Non-Recurrent Laryngeal Nerve: a meta-analysis and clinical considerations.

Authors:  Brandon Michael Henry; Silvia Sanna; Matthew J Graves; Jens Vikse; Beatrice Sanna; Iwona M Tomaszewska; R Shane Tubbs; Jerzy A Walocha; Krzysztof A Tomaszewski
Journal:  PeerJ       Date:  2017-03-21       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.